Eagle Pharmaceutical (EGRX) 46.57 $EGRX SHAREHOLDER

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eagle Pharmaceutical (EGRX) 46.57 $EGRX

SHAREHOLDER ALERT: Rosen Law Firm Reminds Eagle Pharmaceuticals, Inc. Investors of Important August 1 Deadline in Class Action - EGRX
GlobeNewswire - Mon Aug 01, 6:00PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period" of the important August 1, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 46.57 (+3.43)

EGRX Investors: The Wagner Firm Announces The Filing Of A Securities Class Action On Behalf of Eagle Pharmaceuticals Inc. Investors
BusinessWire - Mon Aug 01, 12:40PM CDT
The Wagner Firm announces the filing of a class action lawsuit on behalf of investors who purchased Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the "Class Period". Eagle investors have until August 1, 2016 to file a lead plaintiff motion.
EGRX: 46.57 (+3.43)

3-DAY DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Fri Jul 29, 10:59AM CDT
LOS ANGELES, CA / ACCESSWIRE / July 29, 2016 / Lundin Law PC (the "Firm" announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
EGRX: 46.57 (+3.43)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 29, 8:27AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 46.57 (+3.43)

INVESTOR NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Tue Jul 26, 1:35PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period" are encouraged to contact the firm in advance of the August 1, 2016 lead plaintiff motion deadline.
EGRX: 46.57 (+3.43)

August 1 Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming Deadline in the Class Action Lawsuit Against Eagle Pharmaceuticals Inc.
BusinessWire - Tue Jul 26, 11:20AM CDT
Law Offices of Howard G. Smith reminds investors of the upcoming August 1, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of a class (the "Class" of investors who purchased Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) securities between February 23, 2016 and March 18, 2016, inclusive (the "Class Period". Eagle investors have until August 1, 2016 to file a lead plaintiff motion.
EGRX: 46.57 (+3.43)

APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals Inc. and Reminds Investors with Losses to Contact the Firm
ACCESSWIRE - Tue Jul 26, 10:43AM CDT
IRVINE, CA / ACCESSWIRE / July 26, 2016 / Khang & Khang LLP (the "Firm" announces that a class action lawsuit was filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period", are encouraged to contact the Firm prior to the August 1, 2016 lead plaintiff motion deadline.
EGRX: 46.57 (+3.43)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Lawsuit Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Tue Jul 26, 9:05AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 46.57 (+3.43)

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Eagle Pharmaceuticals, Inc. - EGRX
GlobeNewswire - Mon Jul 18, 5:48PM CDT
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Eagle Pharmaceuticals, Inc. securities (NASDAQ:EGRX) from February 23, 2016 through March 18, 2016, both dates inclusive (the "Class Period". The lawsuit seeks to recover damages for Eagle Pharmaceuticals investors under the federal securities laws.
EGRX: 46.57 (+3.43)

IMPORTANT SHAREHOLDER NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Eagle Pharmaceuticals Inc. And Reminds Investors with Losses To Contact The Firm
BusinessWire - Mon Jul 18, 11:29AM CDT
Lundin Law PC announces a class action lawsuit has been filed against Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (Nasdaq: EGRX) concerning possible violations of federal securities laws between February 23, 2016 and March 18, 2016 (the "Class Period". Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
EGRX: 46.57 (+3.43)

INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Eagle Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
PR Newswire - Fri Jul 08, 10:06AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) securities between February 23, 2016 through March 18, 2016.
EGRX: 46.57 (+3.43)

IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Eagle Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Wed Jun 22, 4:51PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (Nasdaq: EGRX). Investors who purchased or otherwise acquired shares between February 23, 2016 and March 18, 2016 (the "Class Period", are encouraged to contact the firm in advance of the August 1, 2016, lead plaintiff motion deadline.
EGRX: 46.57 (+3.43)

INVESTOR ALERT: Investigation of Eagle Pharmaceuticals Inc. Announced by Law Offices of Howard G. Smith
BusinessWire - Wed Jun 22, 1:39PM CDT
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. ("Eagle" or the "Company" (NASDAQ: EGRX) concerning the Company and its officers' possible violations of federal securities laws.
EGRX: 46.57 (+3.43)

EAGLE PHARMACEUTICALS INVESTOR ALERT: Hagens Berman Reminds Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors of August 1, 2016 Lead Plaintiff Deadline in Securities Class Action
GlobeNewswire - Tue Jun 21, 3:00AM CDT
The following statement is being issued by Hagens Berman Sobol Shapiro LLP:
EGRX: 46.57 (+3.43)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Eagle Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
GlobeNewswire - Mon Jun 20, 10:51AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 46.57 (+3.43)

Lifshitz & Miller Law Firm Announces Investigation of CBL & Associates Properties, Inc., Eagle Pharmaceuticals, Inc., HCP, Inc., Immunomedics, Inc., Infinity Pharmaceuticals Inc., Neovasc, Inc., and Unilife Corporation
PR Newswire - Fri Jun 17, 6:09PM CDT
CBL & Associates Properties, Inc. (CBL)Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the CBL board. Specifically, on May 24, 2016, the Wall Street Journal reported investigations concerning CBL officials falsifying information on financial statements to banks when applying for financial arrangements.
IMMU: 2.80 (+0.15), HCP: 39.45 (+0.22), UNIS: 3.48 (-0.06), CBL: 12.19 (-0.10), INFI: 1.69 (+0.01), EGRX: 46.57 (+3.43), NVCN: 0.58 (+0.04)

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 - EGRX
ACCESSWIRE - Wed Jun 15, 9:04AM CDT
NEW YORK, NY / ACCESSWIRE / June 15, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 46.57 (+3.43)

Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Tue Jun 14, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
LDRH: 36.98 (-0.02), CBL: 12.19 (-0.10), TRXC: 1.30 (-0.05), EGRX: 46.57 (+3.43), NVCN: 0.58 (+0.04)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eagle Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - EGRX
PR Newswire - Fri Jun 10, 4:42PM CDT
Pomerantz LLP announces that a class action lawsuit has been against Eagle Pharmaceuticals, Inc. ("Eagle Pharmaceuticals" or the "Company" (NASDAQ: EGRX) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, and docketed under 16-cv-03091, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Eagle Pharmaceuticals securities between February 23, 2016 and March 18, 2016 inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
EGRX: 46.57 (+3.43)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Eagle Pharmaceuticals, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 1, 2016 -- EGRX
Marketwired - Fri Jun 10, 11:37AM CDT
NEW YORK, NY--(Marketwired - June 10, 2016) - The following statement is being issued by Levi & Korsinsky, LLP:
EGRX: 46.57 (+3.43)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Exploring Creation: A Fresh Look at Genesis

Updated Category News Views 88

Opening Up Genesis in a New Light Hey, if you’re like most folks, you’ve probably heard Genesis framed as the battleground for science versus religion debates, right? Enter into this mix a fresh take with Robert E. Franzen’s new book, The Narration of Creation. This book asks you to overlook those grand philosophical fights and instead focus on the narrative itself....

Continue Reading
Ave7® Pioneers AI-Driven Marketplace Evolution

Updated Category News Views 84

AI Reshapes the Agency Paradigm Nobody saw this coming a decade ago, but here we are—AI's taking the wheel, but with humans still riding shotgun. The agency world, particularly the one dealing with e-commerce giants like Amazon, Walmart, and Target, has flipped on its head. Ave7® steps up as the frontrunner, adapting faster than a broker's reflex after a market bell....

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 122

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 167

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Lennar Faces Legal Heat Over Alleged Misleading Statements

Updated Category News Views 130

Rumbling Legal Drama with Lennar Corporation Every trader knows the uneasy feeling when a stock you're eyeing takes a surprising nosedive on some legal muck coming out of the woodwork. Well, it's Lennar Corporation's turn in the spotlight for all the wrong reasons. They're getting slapped with a class action lawsuit by investors claiming the company pulled a fast one...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
equipifi's BNPL Shop: New Ammo for Credit Unions

Updated Category News Views 149

equipifi's 'Shop': The Big Play in Banking Look, here’s the deal—equipifi just lobbed a new grenade into the finance battlefield, arming credit unions and community banks with 'Shop', their own Buy Now, Pay Later (BNPL) platform. The goal? To put them toe-to-toe with the big fintech wolves—something these smaller guys desperately needed. It's a meaty move, no...

Continue Reading

Top 5 Most Recently Viewed Articles

SpinLaunch's Innovative Technology Set to Transform Satellite Deployment

Updated Category News Views 545

Revolutionizing Satellite Launches with Kinetic Energy SpinLaunch has achieved a remarkable milestone by securing $30 million in a Series C funding round, propelled by the support of ATW Partners and Kongsberg Defence and Aerospace. This brings the total amount raised by the company to an impressive $203 million, demonstrating robust confidence in its innovative approach...

Continue Reading
Micron Technology’s Remarkable Q4 Performance Driven by AI Boom

Updated Category News Views 91

Micron Technology Proves Analysts Wrong with Impressive Earnings Micron Technology, Inc. delivered a phenomenal earnings report that surprised many doubters and analysts, reporting a nearly 100% increase in revenues year-over-year. This significant growth was largely attributed to the booming demand for artificial intelligence (AI) solutions. It’s noteworthy that prior...

Continue Reading
M&T Bank Corporation Declares Quarterly Dividends for Preferred Stock

Updated Category News Views 107

Quarterly Cash Dividends Announced by M&T Bank Corporation M&T Bank Corporation (NYSE: MTB) has declared its quarterly cash dividends for its series of perpetual preferred stock. This announcement comes as part of M&T's commitment to provide consistent returns to its shareholders. Details of the Dividends The company specified two significant dividend payouts. The first...

Continue Reading
Market Trends: Powell's Impact and Tech Earnings in Focus

Updated Category News Views 171

Market Overview: A Day of Mixed Signals In a climate filled with uncertainty, U.S. equities showed a mixed performance, reflecting investors' cautious approach ahead of a crucial Federal Reserve policy decision. The Dow Jones Industrial Average (DJIA) edged up by 0.2%, reaching 47,681.66, driven by gains in industrials and energy sectors. Meanwhile, the S&P 500 (SPX)...

Continue Reading
Revolutionizing Urinary Incontinence Treatment with Altaviva™

Updated Category News Views 296

Introducing the Altaviva™ Device by Medtronic The Altaviva™ device is set to change the landscape of treating urge urinary incontinence. Medtronic plc (NYSE: MDT), a leader in healthcare innovation, has received FDA approval for this remarkable implantable tibial neuromodulation device. This device targets a significant health issue affecting millions, making...

Continue Reading